Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM +3.23%37 EV-to-FCF is -11.13 as of Sep. 12, 2026. GuruFocus rates BSEM with a GF Score™ of 37/100. The stock has 6 warning signs investors should review. Among 315 Biotechnology companies, BioStem Technologies ranks better than 70.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioStem Technologies's Enterprise Value is $71.47 Mil.
BioStem Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.42 Mil. Therefore, BioStem Technologies's EV-to-FCF for today is -11.13.
The historical rank and industry rank for BioStem Technologies's EV-to-FCF or its related term are showing as below:
BSEM'
s EV-to-FCF Range Over the Past 10 Years
Min: -431.98 Med: -17.13 Max: 16.01
Current: -11.13
During the past 13 years, the highest EV-to-FCF of BioStem Technologies was 16.01. The lowest was -431.98. And the median was -17.13.
BSEM's EV-to-FCF is ranked better than 70.79% of 315
companies
in the Biotechnology industry
Industry Median: 15.06
vs BSEM: -11.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioStem Technologies's PE Ratio (TTM) for today is calculated as:
BioStem Technologies's share price for today is $4.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioStem Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioStem Technologies EV-to-FCF Related Terms
BioStem Technologies EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's EV-to-FCF falls into.
BioStem Technologies's current Enterprise Value is $71.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioStem Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a EV-to-FCF of -11.13 as of Sep. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #92 out of 315 companies in the Biotechnology industry, placing it in the top 29.2%.
Is BioStem Technologies' EV-to-FCF too high?
BioStem Technologies' current EV-to-FCF is -11.13. Based on the distribution chart, BioStem Technologies ranks #92 out of 315 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' EV-to-FCF compare to IBIO and CSBR?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #92 out of 315 companies for EV-to-FCF. This puts BioStem Technologies in the upper half of its industry. The industry median EV-to-FCF is 15.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.06, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current EV-to-FCF is -11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current EV-to-FCF of -11.13. The current EV-to-FCF is -11.13. BioStem Technologies' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current EV-to-FCF is -11.13 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
37GF Score
Get the complete analysis for BSEM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
